MRI Study of OnabotulinumtoxinA (OnabotA) Effect on Jaw Muscle Pain
MRI-based Comparison of OnabotulinumtoxinA (OnabotA) Versus Placebo Injections to the Temporalis and Masseter Muscles in the Management of Myofascial Pain Syndrome: A Randomized Clinical Trial
The goal of this clinical trial is to learn which magnetic resonance images are best able to assess and predict if a participant with masticatory myofascial pain syndrome will benefit from Botox injections, as compared to placebo (saline, salt water).
The main questions the study aims to answer are:
- Will diffusion MR images will be best able to assess and predict if a participant with masticatory myofascial pain syndrome will benefit from Botox injections?
- Will Botox injections reduce masticatory myofascial pain and improve jaw function?
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Peter Chernek
- Phone Number: 646-962-5951
- Email: pec4005@med.cornell.edu
Study Locations
-
-
New York
-
New York, New York, United States, 10065
- Weill Cornell Medicine
-
Contact:
- Peter Chernek
- Phone Number: 646-962-5951
- Email: pec4005@med.cornell.edu
-
Principal Investigator:
- Gwendolyn Reeve, D.M.D., FACS
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participant is at least 18 years of age
- Participant has a unilateral or bilateral myofascial pain diagnosis according to the Diagnostic Criteria for Temporomandibular Disorders (DC/TMD), diagnosed by a provider
Exclusion Criteria:
- Participant is pregnant, breastfeeding, or plans to become pregnant
- Participant has known hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation
- Participant has received Botox within the past 4 months
- Participant cannot undergo an MRI. Reasons a participant cannot undergo MRIs for this study include having a pacemaker or having claustrophobia
- Participant has dental implants with metal on the same side/sides of their jaw pain
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo Injections
|
4mL
Other Names:
|
|
Active Comparator: Botox Injections
|
100 units/4mL.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change of muscle fiber diameter of jaw muscles between baseline and 3 month follow up.
Time Frame: Baseline; 3 months
|
Measured by Diffusion MRI in micrometers |
Baseline; 3 months
|
|
Change of muscle fiber permeability of jaw muscles between baseline and 3 month follow up.
Time Frame: Baseline; 3 months
|
Measured by Diffusion MRI in cm/sec |
Baseline; 3 months
|
|
Change of tissue diffusivity of jaw muscles between baseline and 3 month follow up.
Time Frame: Baseline; 3 months
|
Measured by Diffusion MRI in micrometer2/millisecond |
Baseline; 3 months
|
|
Change of pseudo-diffusivity of jaw muscles between baseline and 3 month follow up.
Time Frame: Baseline; 3 months
|
Measured by Diffusion MRI in micrometer2/millisecond |
Baseline; 3 months
|
|
Change of perfusion fraction of jaw muscles between baseline and 3 month follow up.
Time Frame: Baseline; 3 months
|
Measured by Diffusion MRI (no units) |
Baseline; 3 months
|
|
Change of T2 (transverse relaxation time) of jaw muscles between baseline and 3 month follow up.
Time Frame: Baseline; 3 months
|
Measured by MRI in milliseconds |
Baseline; 3 months
|
|
Change of T2* (effective transverse relaxation time) of jaw muscles between baseline and 3 month follow up.
Time Frame: Baseline; 3 months
|
Measured by MRI in milliseconds |
Baseline; 3 months
|
|
Change of FF (fat fraction) of jaw muscles between baseline and 3 month follow up.
Time Frame: Baseline; 3 months
|
Measured by MRI (no units) |
Baseline; 3 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from Baseline in Visual Analog Scale Score at 1 month
Time Frame: Baseline; 1 month
|
The Visual Analog Scale ranges from 0 to 10, where higher scores indicate more pain. |
Baseline; 1 month
|
|
Change from Baseline in Visual Analog Scale Score at 3 months
Time Frame: Baseline; 3 months
|
The Visual Analog Scale ranges from 0 to 10, where higher scores indicate more pain. |
Baseline; 3 months
|
|
Change in jaw function, assessed by Jaw Function Limitation Score (JFLS) from baseline to 1 month.
Time Frame: Baseline; 1 month
|
The Jaw Function Limitation Score (JFLS) ranges from 0 to 8, where higher scores indicate more limitation. |
Baseline; 1 month
|
|
Change in jaw function, assessed by Jaw Function Limitation Score (JFLS) from baseline to 3 months.
Time Frame: Baseline; 3 months
|
The Jaw Function Limitation Score (JFLS) ranges from 0 to 8, where higher scores indicate more limitation. |
Baseline; 3 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Gwendolyn Reeve, D.M.D., FACS, Weill Medical College of Cornell University
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Amino Acids, Peptides, and Proteins
- Proteins
- Biological Factors
- Hydrolases
- Enzymes
- Enzymes and Coenzymes
- Inorganic Chemicals
- Chlorine Compounds
- Botulinum Toxins
- Metalloendopeptidases
- Endopeptidases
- Peptide Hydrolases
- Metalloproteases
- Bacterial Proteins
- Bacterial Toxins
- Toxins, Biological
- Sodium Compounds
- Chlorides
- Hydrochloric Acid
- Botulinum Toxins, Type A
- Sodium Chloride
Other Study ID Numbers
Other Study ID Numbers
- 26-06030338
- R33AT012270 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
De-identified data and de-identified MR images
IPD Sharing Time Frame
Start date - end of study End date - N/A
IPD Sharing Access Criteria
Investigators who are approved by the NIH HEAL Initiative (Helping to End Addiction Long-Term) or the National Institutes of Health (NIH)
IPD Sharing Supporting Information Type
- ANALYTIC_CODE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.